Cannabis Use Disorder

Cannabis Use Disorder is a problematic pattern of cannabis use leading to clinically significant impairment or distress. While cannabis has a lower dependence potential than substances like nicotine or opioids, regular heavy use — especially of high-potency products, and particularly when starting in adolescence — carries genuine risks, including dependence, cognitive effects, and psychiatric complications.

Cannabis Use Disorder is a problematic pattern of cannabis use leading to clinically significant impairment or distress, manifested by two or more of eleven criteria within a 12-month period, covering impaired control, social impairment, risky use, tolerance, and withdrawal. Severity is specified as mild, moderate, or severe.

Cannabis acts on the brain's endocannabinoid system (CB1 receptors), deeply involved in reward, mood, and — particularly relevant in adolescents — ongoing brain development. Heavy, frequent use of high-potency cannabis, increasingly available in many markets, is associated with a higher risk of dependence and psychiatric complications compared to lower-potency, occasional use. Adolescent-onset use carries particular risk given the still-developing brain's heightened sensitivity to cannabis's effects.

• Early age of first use, particularly adolescence
• High-frequency or high-potency use
• Family history of substance use disorders
• Co-occurring mental health conditions, particularly relevant given cannabis's association with psychosis risk in vulnerable individuals
• Family or peer cannabis use
• Easy availability

THC, the primary psychoactive component of cannabis, binds to CB1 cannabinoid receptors, densely distributed in brain regions involved in reward, memory, and coordination. Chronic heavy use leads to downregulation of these receptors, producing tolerance and withdrawal symptoms on cessation. In adolescents, whose endocannabinoid system is still involved in normal brain maturation, heavy use may interfere with this developmental process. Cannabis use, particularly high-potency products used frequently, has also been associated with increased risk of triggering or worsening psychotic symptoms in vulnerable individuals.

• Strong cravings for cannabis
• Unsuccessful attempts to cut down or quit
• Significant time spent obtaining, using, or recovering from use
• Tolerance — needing more for the same effect
• Withdrawal symptoms when stopping after regular heavy use — irritability, anxiety, sleep difficulty, decreased appetite, restlessness, depressed mood
• Continued use despite awareness of physical or psychological problems it may be causing or worsening
• Giving up important activities in favor of use

• Two or more of eleven criteria within a 12-month period
• Causes significant distress or impairment
• Severity specified as mild, moderate, or severe

Conditions a psychiatrist will consider and rule out before confirming this diagnosis:

Occasional/social cannabis use

Without meeting the dependence criteria threshold.

Other substance use disorders

Frequently co-occurring.

Primary psychiatric conditions

Cannabis use may be a coping mechanism for underlying anxiety or sleep problems, though this doesn't preclude a co-occurring cannabis use disorder if criteria are met.

Cannabis-induced psychotic disorder vs. an underlying primary psychotic disorder

Requires careful longitudinal assessment of whether symptoms persist beyond the period of intoxication.

• Clinical interview and detailed use history (frequency, potency, route of use)
• Screening tools such as the Cannabis Use Disorders Identification Test
• Screening for co-occurring substance use and psychiatric conditions, particularly psychotic symptoms, anxiety, and depression
• Assessment of withdrawal symptoms if considering cessation

Psychosocial treatment is the primary approach, since no medication is specifically approved for Cannabis Use Disorder. Motivational Enhancement Therapy and Cognitive Behavioral Therapy have the best evidence, and contingency management approaches also show benefit.

No medication is specifically approved

Medications may manage specific withdrawal symptoms or co-occurring conditions, such as antidepressants for co-occurring depression or anxiety, under psychiatric guidance.

Motivational Enhancement Therapy

Builds internal motivation for reducing or stopping use.

Cognitive Behavioral Therapy

Addresses triggers, cravings, and relapse prevention strategies.

Contingency management

Provides structured incentives for verified abstinence, particularly effective combined with other approaches.

• Identify and avoid personal triggers for use
• Build alternative coping strategies for stress, anxiety, or sleep difficulties cannabis may have been used to manage
• Engage in alternative rewarding activities
• Build a supportive social network not centered around cannabis use
• Be aware of the significantly higher potency of many modern cannabis products compared to previous decades

With appropriate psychosocial treatment, meaningful reduction or cessation of problematic use is achievable for most people. Withdrawal symptoms, while uncomfortable, are not medically dangerous in the way alcohol or opioid withdrawal can be and typically resolve within 1–2 weeks. Ongoing heavy use of high-potency products, especially with adolescent onset, carries increased long-term risk of cognitive effects and psychiatric complications.

• Delaying age of first use, particularly avoiding use during adolescence
• Public education about the risks of high-potency products
• Screening in primary care or school settings for problematic patterns before they become entrenched
• Addressing co-occurring mental health conditions that may drive self-medication

Understand that cannabis, while often perceived as low-risk, can produce a genuine substance use disorder, particularly with frequent, high-potency use. Avoid minimizing concerns based on outdated assumptions of cannabis being 'harmless,' support treatment engagement particularly if psychiatric symptoms — especially psychotic symptoms, which warrant urgent attention — emerge alongside use, and be aware that adolescent use carries particular developmental risk.

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th Edition, Text Revision (DSM-5-TR).
2. World Health Organization. International Classification of Diseases, 11th Revision (ICD-11).
3. National Institute on Drug Abuse (NIDA).